Pharma Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is striving to close with Tresiba and Xultophy, and the limitations of Hungary’s regulatory framework. Zsolt, you took over the helm of Novo Nordisk Hungary in 2012, after…
See our Cookie Privacy Policy Here
